International Journal of Pharmacy and Industrial Research (IJPIR)

ISSN:2231-6567

IJPIR |Volume 13 | Issue 1 | Jan - Mar - 2023
Available online at: www.ijpir.com

Review article Psoriasis

Psoriasis and its treatment using a topical delivery system

J. Anantha Lakshmi*

Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad, Telangana, India.

***Corresponding Author: J. Anantha Lakshmi**
Published on: 19.02.2013

ABSTRACT

Psoriasis is known as a complex, long-lasting skin illness that can have a significant impact on patients' physical and mental health. It occurs when the immune system delivers erroneous signals that accelerate the skin's cell cycle. Numerous drugs that can be administered orally and topically must be incorporated into the psoriasis administration regimen. The topical route circumvents the hepatic first-pass effect, enables continuous drug delivery, has fewer adverse effects, and enhances patient compliance. Emerging technology for the development of drug-vesicular systems can circumvent the significant limitation of low stratum corneum permeability limit. The configuration of vesicular systems diverges from that of conventional approaches. The variation in composition influences the shape, size, and surface features of self-assembled supra-arrangements. This refers to a variety of transporters, including liposomes, niosomes, and transferosomes. Niosomes are formed by the self-assembly of non-ionic amphiphiles in the presence of additional lipid surfactants in an aqueous environment. Niosomes are biodegradable, non-toxic, amphiphilic in nature, perceptual enhancers, and an expedient in the intonation of drug discharge qualities. This review focuses on empty topical systems intended for the treatment of psoriasis and the efficacy of niosomal topical delivery for psoriasis treatment.

Keywords: Niosomes, Vescicular systems, Topical delivery, Psoriasis, Methotrexate

INTRODUCTION

Psoriasis is a skin disease distressing millions of folks globally. It is clinically designate by erythematous, abruptly delimited papules and smoothed plaques, and concealed by silvery Jmicaceous scale, hyper epidermal propagation extend beyond immune-mediated inflammation, foremost to insightful adverse effects on patient's corporeal, social and conceptual wellbeing. Innumerable proinflammatory cytokines, akin as interleukins (ILs), tumour necrosis factor (TNF), and interferon-γ (IFN-γ), has remain acknowledged. Complex cellular interfaces amid epidermal keratinocytes, mononuclear leukocytes, neutrophils, dendritic cells, and activated T cells, organized through growth factors, chemokines, and cytokines, remain intricate in advance of psoriasis[1-3]. Psoriasis is a chronic, autoimmune disease which performs on the skin. It ensues when the immune system propels out defective signals that hustle up the progress cycle of skin cells. Psoriasis is not contagious. It frequently sources red, scaly patches to perform on the skin, granting individual patients obligate no dermatological indications. The scaly patches often instigated by psoriasis, called psoriatic plaques, remain areas of inflammation and extreme skin production[4,5]. The origin of psoriasis is not effusively implicit. There remain two initial hypotheses almost the practice that ensues in the progress of the disease.

1. The first considers psoriasis as primarily a disorder of excessive growth and reproduction of skin cells. The problem is seen as a fault of the epidermis and its keratinocytes.
2. The second hypothesis sees the disease as being an immune-mediated disorder in which the excessive reproduction of skin cells is secondary to factors produced by the immune system. T cells (which typically help protect the body against infection) become active, migrate to the dermis and trigger the release of cytokines (tumour necrosis factor-alpha TNFα, in particular) which cause inflammation and the rapid production of skin cells. It is not known what initiates the activation of the T cells[6, 7].

Mechanism of psoriasis

Psoriasis ensues further probable in dry skin than oily or well-moisturized skin, and explicitly subsequently an exterior skin injury akin as an abrasion or cut (Koebner phenomenon). Psoriasis has an enormous hereditary constituent, and sundry genes remain accompanying through it, but it remains not clear how those genes graft organized. Furthermost of them encompass the immune system, predominantly the foremost histocompatibility complex (MHC) and T cells. Individual variations (mutations) of those genes are commonly found in psoriasis[8, 9].

In psoriasis, immune cells transport after the dermis to the epidermis, where they stimulate skin cells (keratinocytes) to upsurge. Psoriasis ensures not appear to be a definite autoimmune disease. In an autoimmune disease, the immune system complicates an exterior antigen through a typical body constituent and assaults them both. Nevertheless in psoriasis, the inflammation doesn't appear to be instigated by exterior antigens (though DNA ensures need an immunostimulatory outcome). Immune cells akin as dendritic cells and T cells passage from the dermis to the epidermis, secreting chemical signals, corresponding as tumour necrosis factor-α, interleukin-1β, and interleukin-6, that source inflammation, and interleukin-22, which origins keratinocytes to escalate[10]. It remains an intricate interface amid reformed keratinocyte propagation & distinction, inflammation & immune dysregulation. The initial variations remain vascular. There is swelling & intercellular broadening of endothelial cells monitored by deregulation of mast cells round post-capillary venules. Hours later actuated macrophages perform in the lower epidermis wherever there is the loss of desmosome tonofilament complexes. Lastly, lymphocytes & neutrophils seem. Tonofilaments remain declined in number and diameter and typical dearth aggregation. Keratohyaline granules remain reduced in size and number.

The cornified cells uphold organelles and nucleus as parakeratotic cells. The basal keratinocytes spectacle cytoplasmic practices extended into the dermis over gaps in the basal lamina, and they relate with disease activity[11]. The intercellular spaces amid all epidermal cells remain amplified since of deficit in the glycoprotein rich cell surface coat. The spongiform pustule of Kogoj, one of the utmost distinctive sorts of psoriasis, remains positioned in the upmost portion of spinous and granular layers. Here neutrophils lie intercellular in a multilocular pustule in which sponge-like linkage remains poised of degenerated and compacted keratinocytes. The capillary loops in dermal papillae in psoriasis spectacle wider lumen, bridged fenestrations & gaps among endothelial cells. The extravasation of RBCs and inflammatory cells & thickened basement membrane[12]. They might be owing to the admission of amorphous constituents & amassing of collagen fibrils in the Basement Membrane Zone (BMZ)[13].

Epidermal Cell Kinetics

The degree of epidermal cell replication remains distinctly intensified, as directed by the more significant number of basal and suprabasal mitotic data. The mitotic action diverges in altered lesions & even inner the similar lesion. It associates through the degree of parakeratosis. Prompt research advised such the transit time of cells after the basal cell layer to uppermost row remains abridged to 7 days in psoriasis from 53 days in normal epidermis[14-17]. Auxiliary examinations revealed the germinative cell cycle shortened from 311 to 36 hrs, i.e. eight fold quicker propagation in psoriasis, doubling of proliferative cell propagation in psoriasis from 27000 to 52000 cells/sq mm of epidermal surface area, 100% of germinative cells of epidermis come into growth fraction as a substitute of merely 60% for normal subjects. Conversely, alternative revision indicated a particular the germinative cell cycle time in the normal epidermis is 200 hrs whereas in psoriasis, it remains only two-fold faster, i.e. 100 hrs. The basis of cycling cells in suprabasal layers remains not yet well distinct. It might stay an extended population of basal keratinocytes or might be enrolled from transit-amplifying cells (TAC) which remain suprabasal keratinocytes stanch to a terminal distinction that endures rounds of enlarging partitions beyond the basal layer. Keratin revisions advocate TAC subsequently they precise K1/K10 & K6/K16 keratins and not K5/k14 as basal keratinocytes do[18-20].

Keratinocyte Differentiation

Keratinocytes endure a practice of discrepancy as they migrate mounting over the epidermis from the basal layer to the cornified layer once numerous essential proteins remain synthesized. One particular protein family is keratins that remain intermediate filaments, institute in the cytoplasm of all epithelial cells. Exploration spectacle that in normal epidermis K5/K14 remain articulated in basal keratinocytes and K1/K10 are uttered in suprabasal keratinocytes. Involucrin, one of the substantial pioneer proteins of cornified cell casing remain acknowledged greater in granular & cornified layers[21]. In psoriatic skin, basal keratinocytes endure to precise K5/K14.

Nevertheless keratins K1/K10 remain substituted by so-called hyperactive proliferation-associated keratins K5/K16. Correspondingly, involucrin uttered impulsively in minor suprabasal layers. K17 similarly institute in upper suprabasal keratinocytes though they frequently remain institute in profound external root sheath of the hair follicle[22].

Condition Aggravating Psoriasis

Circumstances that obligate remain reported as escorting a deteriorating of the disease embrace infections, stress, and variations in season and climate. Certain medicines comprising lithium salt, beta-blockers and the Antimalarial drug chloroquininine obligate remain described to elicit or exacerbate the disease. Undue alcohol depletion, smoking and obesity might impair psoriasis. Personalities anguish from the innovative effects of the Human immunodeficiency virus (HIV), frequently reveal psoriasis[23].

Severity

The degree of intensity remains mostly established on the ensuing aspects: the fraction of body surface area pretentious; disease activity (degree of plaque redness, thickness and scaling); retort to preceding remedies; and the influence of the disease on the individual. Mild (affecting less than 3% of the body), moderate (affecting 3-10% of the body) or severe[24].

Pathogenesis

The inflammatory conduits active in psoriasis and the respite of the clinical deviations overlay, but likewise spectacle discrete variances such account for the diverse phenotype and management consequences. The foremost clinical outcomes in psoriasis remain evident at the outermost layer of the skin,

that stands through up of keratinocytes. Nevertheless, the advance of the psoriatic remains not constrained to inflammation in the epidermal layer. Still, it relatively is shaped by the interaction of keratinocytes through numerous dissimilar cell sorts spanning the dermal layer of the skin[25]. The pathogenesis of psoriasis can be abstracted into an initiation phase probably triggered by trauma, infection, or drugs and a conservation phase considered by a chronic clinical progression.

Treatment of Psoriasis[26-28]

There are some different treatment options for psoriasis. It includes topical, oral, systemic, Psoriasis treatment aimed to:

- Interfere with the cycle which sources an amplified production of skin cells, thus reducing inflammation and plaque development.
- Confiscate scale and smooth the skin, which remains predominantly exact of topical managements that you apply to your skin.

Topical drug delivery in Psoriasis

Skin membrane allows penetration of all material to some extent via stratum corneum through intercellular lipids[29]. The state of hydration of stratum corneum is one of the essential factors in determining the rate of percutaneous absorption. In psoriasis, there is rigidization of the skin increased the level of cholesterol (CHOL) and fall in the level of ceramide. Numerous topical medicinal proxies remain obtainable for the management of psoriasis as explored in Table 1; none of them can be considered as a superlative drug molecule[30]. This might be owing to an intrinsic side effect or their inadequate unification in a predictable vehicle, due to variation in physicochemical characteristics of carrier and active component used degree of drug absorption through skin vary[31]. A formulation like cream, ointment, and lotion are frequently used for topical delivery of anti-psoriatic agents.

Table 1: List of drugs encapsulated in the topical carrier system & their advantages over a conventional system

Drugs used for treating psoriasis	Novel drug delivery system	Advantages over conventional drug delivery system
Terpenoids (triptolide)	Solid-lipid nanoparticles	Improved penetration
Methotrexate	Ethosomes[31],niosomes[32], liposomes[33]	Improved therapeutic index, improved healing properties
Cyclosporine	Solid-lipid nanoparticles[30]	Enhanced site-specificity
Corticosteroid	Skin-lipid liposomes[34]	Improved skin delivery
Retinoids	Liposomes [35]	Improved penetration
Tacrolimus	Nanoparticles[36] Liposomes[37]	Improved skin transport effect
Temoporfin	Liposomes [33]	Improved topical delivery
Dithranol	Liposomes[23] Niosomes	Devoid of irritation & staining
Coal tar	Lecithinized coal tar formation, lipid-coated microparticles[38-40]	Better anti-psoriatic activity, meet skin irritation challenges.
5- aminolevulinic acid	Ethosomes [41]	Enhanced penetration
Dyphylline	Liposomes [42]	Improved penetration properties
Psoralen	Solid-lipid nanoparticles[43]	Increased skin penetration as well provide controlled release of drug
Tamoxifen	Liposomes [44]	Enhanced skin retention of drug molecule as well skin permeation

Niosomes as a drug delivery system

Niosomes remain as one of the encouraging drug delivery methods in the management of skin ailments. When pragmatic topically, niosomes can augment the residence time of the medication in the stratum corneum and epidermis, though the systemic absorption of the medication can be abridged. They similarly upsurged the horny layer properties by dropping transepidermal water loss and amassed the smoothness via replacing lost skin lipids[45] Both niosomes and liposomes remain equiactive in medication distribution impending and both upsurges the drug efficiency as paralleled through that of free-drug. Niosomes remain desired over liposomes since of the former unveil high chemical stability and economy. One of the details for formulating niosomes remains that they adopt more excellent chemical stability of the surfactants than that of phospholipids, which remain practised in the formulation of liposomes. Owing to the existence of the ester bond, phospholipids remain indeed hydrolysed[42].

Owing to the existence of hydrophilic, amphiphilic and lipophilic moieties in the configuration, these can furnish drug molecules through an extensive array of solubility[43-46]. Niosomes plays a significant role in modelling biological membranes; therefore, they are very useful in the transport and targeting of active agents through the membranes. Niosomal drug delivery system has some advantages over other targeted drug delivery systems. This system prolongs the existence of the drug in the systemic circulation. It perhaps reduces the toxicity due to the delivery of the drug directly to the site of infection.

The therapeutic enactment of the drug molecules can similarly be amended by hindered clearance after the circulation, defending the medicine from the biological environs and constraining effects to target cells. Noisome

prepared of alpha, omega-hexadecyl-bis-(1-aza-18-crown-6) (Bola-surfactant)-Span 80-cholesterol (2:3:1 molar ratio) remains entitled as Bola-Surfactant enclosing noisome. The surfactants adopted in niosome provision ought to be biodegradable, biocompatible and non-immunogenic. Dry products, notorious as proniosomes might be hydrated instantly formerly practice to produce aqueous niosome dispersions. The complications of niosomes akin as accumulation, combination and leaking that deliver surplus accessibility in conveyance, distribution, storage, and dosing. Niosomes behave in vivo similar liposomes, extending the circulation of entangled drug and modifying its organ distribution and metabolic stability. As through liposomes, the properties of niosomes be contingent on the alignment of the bilayer as well as the process of their manufacturing[47].

Topical Delivery of Niosomes in Psoriasis

Niosomes, non-ionic surfactant vesicles, remain extensively premeditated as a substitute to liposomes. These vesicles seem to be analogous to liposomes in expressions of their physical properties. They remain similarly primed in the identical approach and, beneath an assortment of situations, form unilamellar or multilamellar structures. Niosomes improve the hindrances concomitant through liposomes, particularly as chemical instability. They obligate the impending designed for controlled and targeted drug delivery. Niosomes improved the permeation of chemicals and drugs over the stratum corneum (SC). Niosomes to augment penetrability remains their capacity to adapt SC organization; the intercellular lipid barrier in the SC might develop movable and further penetrable by niosome management. Another intention remains varying adsorption and combination of niosomes through the skin's surface that hints to a tremendous thermodynamic activity ascent of medication at the interface. In niosome formulation, non-ionic surfactant itself acts as a permeation enhancer, which might partly contribute to the enhanced niosomal drug permeation[48].

Vesicular Interaction with the Skin

Vesicle–skin interactions were visualized with isolated human SC incubated for 48h and vesicles prepared from CHOL and polyoxyethylene alkyl ether surfactants. Reports stated that, subsequently this development time, liquid, as well as gel-state vesicles, merged at the superficial layer of the SC, nevertheless particularly merely liquid-state vesicles prompted distresses in lipid organization and development of water pools inside the SC. Research indicated merging and adsorption of vesicles against the SC surface, developing stacks of lamellae and asymmetrical assemblies on top of the skin contingent on vesicle configuration. Henceforth, vesicle–skin interfaces remain sturdily reliant on the physiological properties of the vesicular systems[36].

Tretinoin (TRA) is useful in the topical treatment of different skin diseases such as acne vulgaris, ichthyosis and psoriasis[39]. Topical administration of tretinoin provides effective treatment of dermatologic disorders while decreasing systemic exposure and toxicity. However, its topical application is limited by several drawbacks, such as skin irritation, very low water solubility and photostability.

Work has been carried out on tretinoin niosomal formulations. The assimilation of TRA in niosomes might provide the similar aids stated beyond designed for liposomes. Further accurately, the existence of non-ionic surfactants might mend its skin penetration and upsurge its amassing in superficial skin strata. Consequently, vesicular formulations with different techniques (i.e. the film method, the sonication and the extrusion) and different surfactants[43]. The surfactant used is non-ionic surfactants through estereal (Sorbitan esters) or ethereal connection akin as polyoxyethylene lauryl ether (Brij30) to practice stable tretinoin niosomal preparations. In addition to non-ionic surfactant monomers previously adopted in pharmaceutical niosomal preparations (i.e. Span 40 and 60, Brij30). The size of the TRA-incorporated sorbitan ester vesicles was smaller than those of for hydrosoluble molecules. These results confirm the strong influence of the nature of the drug incorporated in the niosomes on vesicle sizes. Dithranol, through an extended account of practice spanning further than 100 years, remains individual of the utmost operative topical remedies in psoriasis. Nevertheless, in the prevailing form of products, it has not stood effusively acknowledged, frequently since of its impatience and staining properties. This prepared a long-standing ultimatum on the researcher's worldwide to pursuit for the amended molecule or preparation. Dithranol (1,8-dihydroxy-9-anthrone), first synthesized in 1916 has since been in clinical use in the treatment of psoriasis. The target organelle designed for dithranol remains mitochondria as healing interaction ensues through the electron transport chain on the inside mitochondrial membrane subsequent in a decline of ATP synthesis[49]. Vesicular methods of dithranol through and deprived of salicylic acid. The preparations once tested on further than 12 patients for four weeks, ascertained to be operative and lacking irritation and staining. It shows dithranol in significantly abridged doses (0.5%) in niosomes might vibrant the psoriasis plaques to counterpart that of 1.15% commercially obtainable dithranol ointment. The benefits of dithranol liposomal in terms of efficiency and amenability (nonirritant and nonstaining). Methotrexate (MTX) is the gold-standard medicine adopted systemically in psoriasis[50].

Vesicle preparation & vesicle characterization

Multilamellar vesicles (MLVs) were prepared according to the film hydration method, as previously reported. The phospholipids or surfactants, cholesterol, DCP and tretinoin (4 mg/ml) remained liquefied in chloroform. The organic solvent remained vacuum vaporized, and the ensuing lipid film remains dried beneath a nitrogen stream for 30 min. The acquired lipid film remained then hydrated beneath mechanical stirring through distilled water (pH 5). The ultimate pH of the primed preparations alternated amid 5.3 and 5.8. Large unilamellar vesicles (LUVs) remained primed by the extrusion practice. Vesicular dispersions showed very low stability and high TRA leakage. Dithranol niosomes were prepared by the thin-film hydration method[51].

The practice of vesicle purification adopted in this revision remains gel chromatography that remains quicker than dialysis, and consequently, might avoid the destabilization of our vesicles, as formerly advocated for C12 sorbitan monoester vesicles. Nevertheless, as described in the investigational section, the purification of these vesicle dispersions remained similarly executed by dialysis. Triton CG 110 vesicles remained not to institute to obligate less

stability, but their incorporation efficiency remained practically 100%.

Transmission electron microscopy (TEM)

The vesicle preparations remained observed by TEM to characterize the microstructure. A drip of vesicle dispersion remained pragmatic to a carbon film-covered copper grid. Furthermost of the dispersion remained blotted from the grid through filter paper to form a thin film specimen that stood stained with 1% phosphotungstic acid[52]. The illustration remained then observed and photographed through a Zeiss EM 109 TEM at a hastening voltage of 80 kV.

Incorporation efficiency (E %)

Sorbitan monostearate (C18) vesicles always showed an increased entrapment efficiency concerning sorbitan monopalmitate (C16) niosomes. These outcomes remain analogous to those described for unsonicated sorbitan monoester niosomes loaded through doxorubicin, endorsing the hypothesis that *E*% might be associated with the hydrophobicity of the alkyl chain of the sorbitan esters. Niosomes acquired from surfactant monomers through an ethereal linkage (Brij 30 and Triton CG 110) continually obtainable a high *E*% which did not appear to be pretentious by the preparation practice of vesicles, the size of that stood precise akin whatever the process practised. Though research advised certain alkyl glycosides smaller than C14 might not form vesicle configurations and might be distant by dialysis, we perceived a high *E*% and good stability for octyl/decyl polyglucoside vesicles. Saturation of lipid domains concerning drug where low PC content provides limited entrapment capacity[53]. The upsurge in the entrapment efficiency remains ascribed to the capacity of CHOL to reinforce the dripping space in the bilayer membranes that in turn consent enriched drug level in liposomes.

Release Study

In vitro diffusion revisions of TRA in a dissimilar vesicle, preparations remained executed over a silicone membrane expending vertical Franz diffusion cells (Rofarma, Milan). The receiver compartment consumed a volume of 7 cm3 and an operative diffusion area of 0.636 cm2. The receptor compartment remained occupied through a hydroalcoholic solution (ethanol: water 50:50) that remained constantly stirred through a small magnetic bar and thermostated at 37 °C all over the experimentations. Approximately 1 ml of respectively vesicle suspension through or deprived of (control) TRA integrated stood positioned on the silicone membrane surface[54]. Then the diffusion cells stood concealed through aluminium foil to preclude light exposure. A methanolic solution of TRA stayed similarly deliberate as an allusion. Illustrations of the delivery solution stood extracted afterwards intervened times of 2, 4, 6, 8 and 24 h and interchanged through a corresponding volume of hydroalcoholic solution to confirm sink circumstances. The illustrations remained diverse through the applicable expanse of I.S. and analyzed by HPLC. At the end of the investigation, illustrations of the donor phase remained analyzed and tested for TRA content and vesicle stability. TRA reclamation after the donor and receptor compartment constantly remained further than 95–96% of the applied dose[55].

CONCLUSION

Due to its adaptability to be tailored for the treatment of psoriasis, vesicular systems have been realised as advantageous carrier systems in numerous scientific fields. Due to the systemic adverse effects associated with their administration, orally given psoriasis medications have limited utility in the treatment of glaucoma. Topical treatment is the basis of treatment for mild to moderate psoriasis and serves as a supplement to systemic treatment for severe disease. However, the efficacy and accessibility of topical treatments for psoriasis remain a significant source of concern. Numerous topical treatments for the treatment of psoriasis continue to be accessible. None of these, however, can be termed an ideal therapeutic molecule. This could be due to their inherent adverse effects or to their insufficient incorporation in predictable vehicles. Niosomal formulation improves permeability and boosts the drug's bioavailability. Niosomes retain a substructure comprised of hydrophilic, amphiphilic, and lipophilic moieties and, as a result, can accommodate pharmacological molecules with a broad range of solubilities. There are three principal forms of niosomes - multilamellar vesicles (MLV, size >0.05 µm), small unilamellar vesicles (SUV, size -0.025-0.05 µm), large unilamellar vesicles (LUV, size >0.10 µm). The vesicles of MLVs demonstrate an increase in confined volume and equilibrium solute distribution. Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous phase to control the pace of drug distribution and to manage different vesicles in the peripheral non-aqueous phase. Niosomes continue to be a viable alternative to liposomes, as liposomes are costly, their ingredients, such as phospholipids, are chemically unstable due to their susceptibility to oxidative deprivation, they require unique storage and practise, and the purity of natural phospholipids is variable. Similar to liposomes, an aqueous suspension of niosomes may indicate accumulation, merging, release, or hydrolysis of encapsulated medicines, hence limiting the shelf-life of niosomes dispersion. Niosome Preparation is time-consuming, requires specialised equipment, and is ineffectual, especially if smaller amounts are required for accurate application or dosage.

REFERENCES

1. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369-75. doi: 10.1038/nature03963, PMID 16163348.
2. Behnam SM, Behnam SE, Koo JY. Smoking and psoriasis. Skinmed. 2005;4(3):174-6. doi: 10.1111/j.1540-9740.2005.03716.x, PMID 15891254.
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. doi: 10.1056/NEJMra0804595, PMID 19641206.

4. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release. 1998;54(2):149-65. doi: 10.1016/s0168-3659(97)00100-4, PMID 9724902.
5. Namdeo A, Jain NK. Niosomes as drug carriers. Ind J Pharm Sci. 1996;58:41-6.
6. Ciotti SN, Weiner N. Follicular liposomal delivery systems. J Liposome Res. 2002;12(1-2):143-8. doi: 10.1081/lpr-120004787, PMID 12604048.
7. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001;219(1-2):61-72. doi: 10.1016/s0378-5173(01)00627-5, PMID 11337166.
8. Hofland HEJ, van der Geest R, Bodde HE, Junginger HE, Bouwstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharm Res. 1994;11(5):659-64. doi: 10.1023/a:1018963910260, PMID 8058633.
9. Abraham W, Downing DT. Interaction between corneocytes and stratum corneum lipid liposomes in vitro. Biochim Biophys Acta. 1990;1021(2):119-25. doi: 10.1016/0005-2736(90)90023-h, PMID 2302392.
10. Peck G. Synthetic retinoids in dermatology. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. Vol. 2. Orlando: Academic press; 1984. p. 391-441.
11. Peinni C, Vigolti M. Drug and cosmetics in relation to the topical treatment of acne: data from a nation wide enquiry. Cosmet Dermatol. 1991;2:17-26.
12. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol. 1992;27(6 Pt 2):S2-7. doi: 10.1016/s0190-9622(08)80252-6, PMID 1460120.
13. Kligman AM, Fulton JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469-76. doi: 10.1001/archderm.1969.01610220097017, PMID 4238828.
14. Elbaum DJ. Comparison of the stability of topical isotretinoin and topical tretinoin and their efficacy in acne. J Am Acad Dermatol. 1988;19(3):486-91. doi: 10.1016/s0190-9622(88)70202-9, PMID 2971693.
15. Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: influence of vehicle, light exposure and dose. J Invest Dermatol. 1988;91(1):56-61. doi: 10.1111/1523-1747.ep12463289, PMID 3385216.
16. Wang JCT, Yusuf M, Liu J; 1995. Skin care composition containing retinoids and liposomes. US Patent US 415975, 3 April.
17. Manconi M, Baroli B, Sinico C, Valenti D, Fadda AM. Liposomes and niosomes for the photoprotection oftretinoin. Proceedings of the international symposium control. Rel. Bioact Mater. 1999;26:477-8.
18. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan trimester (Span 85). Int J Pharm. 1994;105(1):1-6. doi: 10.1016/0378-5173(94)90228-3.
19. Mehrle G, Bonnekoh B, Wevers A, Hegemann L. Anthralin: how does it act and are there more favorable; 1994.
20. Gidwani SK, Singnurkar PS. Composition for delivery of dithranol. India: European Patent Office; 2003. p. 1-14.
21. Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm. 2002;234(1-2):237-48. doi: 10.1016/s0378-5173(01)00971-1, PMID 11839454.
22. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis Phase I and phase II studies. Indian J Dermatol Venereol Leprol. 2007;73(3):157-61. doi: 10.4103/0378-6323.32709, PMID 17558046.
23. Agarwal R, Katare OP, Vyas SP. Preparation and *in vitro* evaluation of liposomal/niosomal delivery systems for anti-psoriatic drug dithranol. Int J Pharm. 2001;228(1-2):43-52. doi: 10.1016/s0378-5173(01)00810-9, PMID 11576767.
24. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Interface Sci. 1995;58(1):1-55. doi: 10.1016/0001-8686(95)00242-I.
25. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan trimester(Span 85). Int J Pharm. 1994;105(1):1-6. doi: 10.1016/0378-5173(94)90228-3.
26. Kiwada H, Niimura H, Fujisaki Y, Yamada S, Kato Y. Application of syntetic alkyl glycoside vesicles as drug carriers. I. Preparation and physical properties. Chem Pharm Bull. 1985;33(2):753-9. doi: 10.1248/cpb.33.753.
27. Israelachvili JN. Intermolecular and surface forces. Sydney: Academic Press; 1985.
28. Patel VB, Misra AN. Encapsulation and stability of clofazimine liposomes. J Microencapsul. 1999;16(3):357-67. doi: 10.1080/026520499289077, PMID 10340220.
29. Duplessis J, Ramachandran C, Weiner N, Muller DG. The influence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage. Int J Pharm. 1996;127(2):273-8. doi: 10.1016/0378-5173(95)04281-4.
30. Redziniak G, Perrier P. Cosmetic application of liposomes. In: Benita S, editor. Microencapsulation: methods and industrial application. New York: Marcel Dekker; 1996. (p. 580pp).
31. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol. 2010;76(6):612-21. doi: 10.4103/0378-6323.72451, PMID 21079304.
32. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564-9. doi: 10.1016/s0190-9622(97)70172-5, PMID 9344194.
33. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-7. doi: 10.1016/s0190-9622(99)70112-x, PMID 10459113.
34. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43(2 Pt 1):281-5. doi: 10.1067/mjd.2000.106374, PMID 10906652.
35. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-4. PMID 11255325.

36. Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release. 2020;327:500-11. doi: 10.1016/j.jconrel.2020.08.039, PMID 32858073.
37. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7. doi: 10.5070/D318W9J736, PMID 15530297.
38. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370(9583):272-84. doi: 10.1016/S0140-6736(07)61129-5, PMID 17658398.
39. Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clin Dermatol. 2001;19(4):489-501. doi: 10.1016/s0738-081x(01)00183-3, PMID 11535394.
40. Kim ST, Jang DJ, Kim JH, Park JY, Lim JS, Lee SY, et al. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie. 2009;64(8):510-14. PMID 19746839.
41. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270(1-2):119-25. doi: 10.1016/j.ijpharm.2003.10.006, PMID 14726128.
42. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 2007;123(2):148-54. doi: 10.1016/j.jconrel.2007.08.005, PMID 17884226.
43. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol. 2007;73(3):157-61. doi: 10.4103/0378-6323.32709, PMID 17558046.
44. Fresta M, Puglisi G. Corticosteroid dermal delivery with skin-lipid liposomes. J Control Release. 1997;44(2-3):141-51. doi: 10.1016/S0168-3659(96)01519-2.
45. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000;5(4):455-64. doi: 10.1081/pdt-100102029, PMID 11109245.
46. Mookkandi SA, Palsamy K, Sivaraman G, Maddiboyina B, Annaraj J, Rajesh J et al. A novel curcumin-loaded PLGA micromagnetic composite system for controlled and pH-responsive drug delivery. Colloids Surf A Physicochem Eng Asp. 2019;573:188-95.
47. Erdogan M, Wright JR, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol. 2002;146(6):964-7. doi: 10.1046/j.1365-2133.2002.04800.x, PMID 12072063.
48. Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S, et al. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res. 2010;20(1):38-48. doi: 10.3109/08982100903030263, PMID 19558347.
49. Bhatia A, Mangat P, Jain B, Singh B, Katare OP. Washability and fabric-staining properties of a novel phospholipid-structured coal tar formulation. J Dermatolog Treat. 2008;19(2):105-10. doi: 10.1080/09546630701537678, PMID 17852641.
50. Fernandez JM, Knudson MB. Method of delivering a lipid-coated condensed-phase microparticle composition. Patent Office; 1995.
51. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol. 2002;146(2):178-88. doi: 10.1046/j.0007-0963.2001.04689.x, PMID 11903225.
52. Touitou E, Shaco-Ezra N, Dayan N, Jushynski M, Rafaeloff R, Azoury R. Dyphylline liposomes for delivery to the skin. J Pharm Sci. 1992;81(2):131-4. doi: 10.1002/jps.2600810206, PMID 1545351.
53. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633-40. doi: 10.1016/j.ejpb.2008.05.008, PMID 18577447.
54. Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes:development, characterization and *in-vitro* evaluation. J Pharm Pharm Sci. 2004;7(2):252-9. PMID 15367383.
55. Bhatia A, Singh B, Bhushan S, Katare OP. Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. Drug Dev Ind Pharm. 2010;36(3):350-4. doi: 10.1080/03639040903173549, PMID 19719395.